Testing the drug liso-cel as a first treatment for adults with lymphoma that starts in the brain and spinal cord
Official title: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a drug called liso-cel in adults with a lymphoma that starts in the brain and spinal cord, who cannot have a transplant.
Read our full plain-language summary
What the trial team says
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Key facts
- Registry number
- NCT07015242
- Stage of testing
- Phase 2
- Conditions studied
- Lymphoma
Where it is running
This trial lists 40 sites.
-
Alpes-Maritimes
- Local Institution - 0111 (Nice)
-
Baden-Wurttemberg
- Local Institution - 0202 (Freiburg im Breisgau)
- Universitätsklinikum Ulm (Ulm)
-
Colorado
- University Of Colorado (Aurora)
-
Florida
- Moffitt Cancer Center (Tampa)
-
France
- CHU de Dijon Bourgogne - Hopital Francois Mitterand (Dijon)
- Chru De Lille - Hopital Claude Huriez (Lille)
- Local Institution - 0112 (Marseille)
- CHU Montpellier (Montpellier)
- Local Institution - 0114 (Paris)
- Local Institution - 0102 (Paris)
- Local Institution - 0108 (Pessac)
- CHU de Rennes - Hopital de Pontchaillou (Rennes)
- Centre Henri Becquerel (Rouen)
- Local Institution - 0110 (Saint-Cloud)
- Local Institution - 0115 (Strasbourg)
- Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole (Toulouse)
- and 1 more in France
-
Germany
- Charité - Universitätsmedizin Berlin (Berlin)
- Local Institution - 0207 (Göttingen)
- Universitätsklinikum Hamburg-Eppendorf (Hamburg)
- Universitätsklinikum Heidelberg (Heidelberg)
- Klinikum Stuttgart - Katharinenhospital (Stuttgart)
-
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Chicago)
-
Loire-Atlantique
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu (Nantes)
-
Massachusetts
- Dana-Farber Cancer Institute (Boston)
-
Missouri
- Washington University School of Medicine in St. Louis (St Louis)
-
New Jersey
- Rutgers Cancer Institute of New Jersey (New Brunswick)
-
New York
- Roswell Park Comprehensive Cancer Center (Buffalo)
- Memorial Sloan Kettering Cancer Center (New York)
-
North Rhine-Westphalia
- Universitätsklinikum Köln (Cologne)
- Universitätsklinikum Essen (Essen)
-
Ohio
- Cleveland Clinic (Cleveland)
- The Ohio State University Comprehensive Cancer Center (Columbus)
-
Pennsylvania
- University of Pennsylvania (Philadelphia)
-
Rhône
- Local Institution - 0103 (Pierre-Bénite)
-
Saxony
- Klinikum Chemnitz gGmbH (Chemnitz)
-
Tennessee
- Sarah Cannon Research Institute Oncology Partners (Nashville)
-
Texas
- MD Anderson Cancer Center (Houston)
-
Washington
- Fred Hutchinson Cancer Center (Seattle)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.